한글목차

울토미리스(성분명: 라브리주맙)는 최초이자 유일한 지속형 C5 보체 억제제이며, 신속하고 완전하며 지속적인 보체 억제 작용을 합니다. 이 약물은 신체 면역 체계의 일부인 말단 보체 캐스케이드의 C5 단백질을 억제하여 작용합니다. 보체 캐스케이드는 조절되지 않고 활성화되면 과잉 반응하여 건강한 세포를 공격합니다. 울토미리스는 성인 환자에게 8주마다 정맥으로 투여합니다.

앞으로 수년간 피부 근염 시장 시나리오는 세계에서 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 업체들은 질병을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, 울토미리스의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 다른 피부근염 치료제들도 울토미리스와 치열한 시장 경쟁을 벌일 것으로 예상되며, 향후 후발주자 신약이 출시되면 시장에 큰 영향을 미칠 것으로 예상됩니다.

주요 7개국의 울토미리스 시장에 대해 조사했으며, 시장의 개요와 2024-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 피부근염에 대한 울토미리스의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(후기 단계 신규 치료법)

제4장 울토미리스 시장 평가

• 피부근염에 대한 울토미리스의 시장 전망
• 주요 7개국 시장 분석
  • 주요 7개국에서 피부근염에 대한 울토미리스의 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제5장 SWOT 분석

제6장 애널리스트의 견해

제7장 부록

제8장 DelveInsight의 서비스 내용

제9장 면책사항

제10장 DelveInsight 소개

제11장 리포트 구입 옵션

영문목차

“"ULTOMIRIS Emerging Drug Insight and Market Forecast - 2032" ” report provides comprehensive insights about ULTOMIRIS for dermatomyositis in the seven major markets. A detailed picture of the ULTOMIRIS for dermatomyositis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ULTOMIRIS for dermatomyositis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ULTOMIRIS market forecast analysis for dermatomyositis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in dermatomyositis.

Drug Summary:

ULTOMIRIS (ravulizumab), the first and only long-acting C5 complement inhibitor, offers immediate, complete, and sustained complement inhibition. The medication works by inhibiting the C5 protein in the terminal complement cascade, a part of the body's immune system. When activated uncontrolled, the complement cascade over-responds, leading the body to attack its healthy cells. ULTOMIRIS is administered intravenously every 8 weeks in adult patients, following a loading dose.

The company is actively recruiting for its registration Phase II/III study, which started in December 2021 and is expected to be completed by November 2024.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ULTOMIRIS description, mechanism of action, dosage and administration, research and development activities in dermatomyositis.
• Elaborated details on ULTOMIRIS regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ULTOMIRIS research and development activities in dermatomyositis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ULTOMIRIS.
• The report contains forecasted sales of ULTOMIRIS for dermatomyositis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for dermatomyositis.
• The report also features the SWOT analysis with analyst views for ULTOMIRIS in dermatomyositis.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ULTOMIRIS Analytical Perspective by DelveInsight

In-depth ULTOMIRIS Market Assessment

This report provides a detailed market assessment of ULTOMIRIS for dermatomyositis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

ULTOMIRIS Clinical Assessment

The report provides the clinical trials information of ULTOMIRIS for dermatomyositis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for dermatomyositis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ULTOMIRIS dominance.
• Other emerging products for dermatomyositis are expected to give tough market competition to ULTOMIRIS and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ULTOMIRIS in dermatomyositis.
• Our in-depth analysis of the forecasted sales data of ULTOMIRIS from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ULTOMIRIS in dermatomyositis.

Key Questions:

• What is the product type, route of administration and mechanism of action of ULTOMIRIS?
• What is the clinical trial status of the study related to ULTOMIRIS in dermatomyositis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ULTOMIRIS development?
• What are the key designations that have been granted to ULTOMIRIS for dermatomyositis?
• What is the forecasted market scenario of ULTOMIRIS for dermatomyositis?
• What are the forecasted sales of ULTOMIRIS in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ULTOMIRIS for dermatomyositis?
• Which are the late-stage emerging therapies under development for the treatment of dermatomyositis?

Table of Contents

1. Report Introduction

2. ULTOMIRIS Overview in Dermatomyositis

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Late-stage Emerging Therapies)

4. ULTOMIRIS Market Assessment

• 4.1. Market Outlook of ULTOMIRIS in dermatomyositis
• 4.2. 7MM Analysis
  • 4.2.1. Market Size of ULTOMIRIS in the 7MM for dermatomyositis
• 4.3. Country-wise Market Analysis
  • 4.3.1. Market Size of ULTOMIRIS in the United States for dermatomyositis
  • 4.3.2. Market Size of ULTOMIRIS in Germany for dermatomyositis
  • 4.3.3. Market Size of ULTOMIRIS in France for dermatomyositis
  • 4.3.4. Market Size of ULTOMIRIS in Italy for dermatomyositis
  • 4.3.5. Market Size of ULTOMIRIS in Spain for dermatomyositis
  • 4.3.6. Market Size of ULTOMIRIS in the United Kingdom for dermatomyositis
  • 4.3.7. Market Size of ULTOMIRIS in Japan for dermatomyositis

5. SWOT Analysis

6. Analysts' Views

7. Appendix

• 7.1. Bibliography
• 7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

11. Report Purchase Options